Florida Cancer Specialists

New Port Richey, Florida 34655

0 studies enrolling now · 8 studies all time

What they study most

Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Chronic Myeloid Leukemia, HER-2 Positive Breast Cancer, Metastatic Neoplasm, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Metastatic or Unresectable Cutaneous Melanoma, mCRPC

Studies at this site

• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer — Completed
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer — Completed
• Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed